TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.
Key numbers for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.
AllSight quality score: 44/100 — a percentile rank of TEVA PHARMACEUTICAL INDUSTRIES LTD’s fundamentals against Manufacturing peers, weakest on financial health. A quality ranking, not a price prediction.
| Market cap | $45.8B |
| P / E | 64.8× |
| P / S | 2.6× |
| EV / EBITDA | 13.8× |
| Gross margin | 52.5% |
| Operating margin | 9.3% |
| Net margin | 4.1% |
| Return on equity | 9.1% |
| ROIC | 7.6% |
| Revenue growth | 4.1% |
| Debt / equity | 2.1× |
| Dividend yield | 0.0% |
Is TEVA PHARMACEUTICAL INDUSTRIES LTD overvalued? P/S looks overvalued vs its 5-year range; EV/EBITDA looks overvalued vs its 5-year range; P/B looks overvalued vs its 5-year range.
Independent of the events above — derived from TEVA PHARMACEUTICAL INDUSTRIES LTD’s own financial statements and shown as context, never as advice.
About AllSight · Editorial standards & method · Contact